<DOC>
	<DOCNO>NCT00941135</DOCNO>
	<brief_summary>To evaluate progression free time patient complete partial response &gt; 30 % evaluated primary tumour ( damage T N ) induction TPF ( Docetaxel , Cisplatin , 5-FU ) treat RT + Cetuximab 2 year .</brief_summary>
	<brief_title>Safety Efficacy Study Patients With Local Advanced Larynx/Hypolarynx Carcinoma Treated With TPF Induction Chemotherapy Followed Hyperfractionated Radiotherapy With Cetuximab</brief_title>
	<detailed_description />
	<mesh_term>Laryngeal Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Patient inform consent must sign start study . Age 18 70 year . Performance Status 01 accord ECOG scale moment inclusion . Life expectancy &gt; 3 month . Confirmed anatomopathologic diagnosis local advance scaly larynx hypolarynx carcinoma III IV stage without evidence distance metastasis , surgery involve total laryngectomy . T3 , T4A , T4B T2 candidate partial laryngectomy . In case T2 location require III IVA stage . Patients medical condition receive neoadjuvant treatment TPF follow hyperfractionated radiotherapy combine cetuximab . Presence injury measurable RECIST criterion . Neutrophils &gt; = 1500/mm3 , platelet &gt; = 150.000/mm3 haemoglobin &gt; =10 g/dL . Renal Function appropriate Hepatic Function appropriate Serum Calcium tight albumine &lt; = 1,25 x upper normal limit ( UNL ) . Nutritional status appropriate : weight loss &lt; 20 % albumine &gt; = 35 g/L . Women childbearing potential men must agree use adequate contraception prior study entry duration study participation . Metastatic disease . Surgical treatment , radiotherapy and/or previous chemotherapy . Another tumour location head neck area different larynx hypo larynx . Another stage different III IVa without distant metastasis resectable disease . Another previous scaly carcinoma Diagnosis another neoplasia last 5 year , except cervix carcinoma situ and/or basocellular cutaneous carcinoma adequately treat . Active infection treat ATB IV , include active tuberculosis VIH . Hypertension control define systolic &gt; = 180 mm Hg and/or diastolic &gt; =130 mm Hg rest . Pregnant/lactating woman . Systemic immune treatment , chronic concomitant , cancer hormone treatment . Another antineoplastic concomitant treatment . Coronary artery disease history heart attack last 12 month high risk arrythmia uncontrolled cardiac insufficiency uncontrolled . EPOC require 3 hospitalization last 12 month . Active ulcus control . Psychiatric illness/social situation would limit compliance study requirement Drug abuse ( except alcohol abuse ) Knowledge Allergic study treatment . Previous treatment Monoclonal antibody . Any experimental treatment previous 30 day start study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2011</verification_date>
</DOC>